As reported by FDA “The U.S. Food and Drug Administration today approved TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox. Though the World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980, there have been longstanding concerns that smallpox could be used as a bioweapon”
The drug maker is SIGA Technologies. Founded in 1995, according to Wiki “SIGA has strong relationship with federal agencies and academic laboratories for its research and development activities. SIGA is providing countermeasures to the Strategic National Stockpile (SNS) and the Department of Defense (DoD), such as Category A pathogens using BSL-3 or -4 work” TrialSite News has learned that they have made shipments to the federal government. They are thinly capitalized with under 50 employees; operating at financial loss and to date generating under $20 million revenue; at the end of 2016 they had approximately $26 million cash in bank. It is probable that this FDA approval will improve their financial position.
See their website https://www.siga.com/
View article here